Basilea Pharmaceutica Company Review & Valuation BSLN
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG, together with its subsidiaries, operates as an integrated biopharmaceutical company. The company focuses on the discovery, development, and commercialization of pharmaceutical products in the therapeutic areas of bacterial and fungal infections, and oncology. It offers isavuconazole, an intravenous and oral antifungal drug for the treatment of invasive mold infections under the name of CRESEMBA worldwide. The company also offers isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis in the United States; and for the treatment of adult patients with invasive aspergillosis and for the treatment of adult patients with mucormycosis for whom amphotericin B is inappropriate in the member states of the European Union. In addition, it provides ceftobiprole, an intravenous antibiotic under the Zevtera/Mabelio name in 13 European and various non-European countries for the treatment of adult patients with community and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. Further, the company is developing BAL101553, an oral and intravenous anti-cancer drug candidate for use as a tumor checkpoint controller that is in Phase I/IIa clinical studies; and has in-licensed BAL3833, an oral anti-cancer drug candidate for use as a panRAF/SRC kinase inhibitor targeting cell proliferation signaling pathways, which is in Phase I clinical development. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
Primary Stock Exchange Listings